Baseline patient characteristics (N = 100)
| Characteristic . | Value . |
|---|---|
| Age at inclusion, median (range), y | 60.5 (32-89) |
| Age group | |
| ≤70 y | 83 (83) |
| >70 y | 17 (17) |
| Sex | |
| Male | 45 (45) |
| Female | 55 (55) |
| ECOG PS | |
| 0 | 75 (75) |
| 1 | 24 (24) |
| 2 | 1 (1) |
| Ann Arbor stage | |
| II | 11 (11) |
| III | 22 (22) |
| IV | 67 (67) |
| Highest diameter >7 cm | |
| No | 69 (69) |
| Yes | 31 (31) |
| Time between biopsy of initial diagnosis and inclusion, median (IQR), mo | 1.6 (1-3) |
| Initial histologic diagnosis (per local assessment) | |
| CD20+ FL grade 2 | 72 (72) |
| CD20+ FL grade 1 | 13 (13) |
| CD20+ FL grade 3a | 9 (9) |
| Other | 6 (6) |
| CD20+ FL grades 1-2 | 5 (5) |
| Low-grade FL | 1 (1) |
| FLIPI group | |
| Low | 17 (17) |
| Intermediate | 40 (40) |
| High | 43 (43) |
| LDH levels >ULN | |
| No | 73 (73) |
| Yes | 27 (27) |
| B symptoms | |
| No | 82 (82) |
| Yes | 18 (18) |
| BM involvement* | |
| No | 47 (52) |
| Yes | 43 (48) |
| Missing | 10 |
| β2-microglobulin levels >ULN* | |
| No | 50 (52) |
| Yes | 46 (48) |
| Missing | 4 |
| Characteristic . | Value . |
|---|---|
| Age at inclusion, median (range), y | 60.5 (32-89) |
| Age group | |
| ≤70 y | 83 (83) |
| >70 y | 17 (17) |
| Sex | |
| Male | 45 (45) |
| Female | 55 (55) |
| ECOG PS | |
| 0 | 75 (75) |
| 1 | 24 (24) |
| 2 | 1 (1) |
| Ann Arbor stage | |
| II | 11 (11) |
| III | 22 (22) |
| IV | 67 (67) |
| Highest diameter >7 cm | |
| No | 69 (69) |
| Yes | 31 (31) |
| Time between biopsy of initial diagnosis and inclusion, median (IQR), mo | 1.6 (1-3) |
| Initial histologic diagnosis (per local assessment) | |
| CD20+ FL grade 2 | 72 (72) |
| CD20+ FL grade 1 | 13 (13) |
| CD20+ FL grade 3a | 9 (9) |
| Other | 6 (6) |
| CD20+ FL grades 1-2 | 5 (5) |
| Low-grade FL | 1 (1) |
| FLIPI group | |
| Low | 17 (17) |
| Intermediate | 40 (40) |
| High | 43 (43) |
| LDH levels >ULN | |
| No | 73 (73) |
| Yes | 27 (27) |
| B symptoms | |
| No | 82 (82) |
| Yes | 18 (18) |
| BM involvement* | |
| No | 47 (52) |
| Yes | 43 (48) |
| Missing | 10 |
| β2-microglobulin levels >ULN* | |
| No | 50 (52) |
| Yes | 46 (48) |
| Missing | 4 |
Data are presented as no. (%) unless otherwise specified. ECOG PS, Eastern Cooperative Oncology Group performance status; FLIPI, Follicular Lymphoma International Prognostic Index; IQR, interquartile range; LDH, lactate dehydrogenase; ULN, upper limit of normal.
Calculated percentages excluded missing data.